Fig. 1: TNBCs have higher PD-L1 expression. | Nature Communications

Fig. 1: TNBCs have higher PD-L1 expression.

From: NPM1 upregulates the transcription of PD-L1 and suppresses T cell activity in triple-negative breast cancer

Fig. 1

a Representative images of immunohistochemical (IHC) staining of PD-L1 in 149 breast cancer tissues (a, PD-L1 negative; b–d, PD-L1 positive). b PD-L1 positive rate in 52 TNBC and 97 non-TNBC patient samples. Tow-side Pearson Chi-square analysis was used to determine the correlation. c Kaplan–Meier analysis for all breast cancer subtypes and TNBC based on PD-L1 expression. Data was analyzed by log-rank test. d PD-L1 mRNA expression in TNBC and non-TNBC in TCGA database (P < 0.0001). For TNBC group, maximum = 4.806, median = 1.28, minimum = −0.265, upper bound (75th percentile) = 1.913, lower bound (25th percentile) = 0.766. For non-TNBC group, maximum = 3.176, median = 0.603, minimum = −0.973, upper bound (75th percentile) = 1.173, lower bound (25th percentile) = 0.129. e Western blot analysis of PD-L1 in TNBC cell lines (MDA-MB-231, HCC1937, BT20, HCC1806, and HS578T) and non-TNBC cell lines (MCF-7, T47D, and SKBR3). f RT-qPCR analysis of PD-L1 mRNA in TNBC and non-TNBC cell lines. Data were presented as mean ± s.d. of three independent experiments. Source data are provided as a Source Data file.

Back to article page